European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

RSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

Heterocyclic Letters is an esteemed journal in the field of synthetic organic chemistry, published by RAMAN PUBL. With ISSN 2231-3087 and E-ISSN 2230-9632, this journal aims to disseminate original research and innovative findings related to heterocyclic compounds, which play a crucial role in medicinal chemistry, material science, and agricultural chemistry. Heterocyclic Letters provides a platform for researchers, professionals, and students to share their insights and advancements, thus fostering academic collaboration and knowledge transfer. The journal is dedicated to maintaining high-quality standards in research publication, making it an essential resource for anyone focused on the latest developments in heterocyclic chemistry. Although it does not currently offer Open Access options, the journal’s rigorous peer-review process ensures that only the most credible and impactful studies are published, contributing significantly to the advancement of the field.

Heteroatom Chemistry is a prominent open-access journal dedicated to advancing the field of heteroatom chemistry, with a particular focus on the chemistry of elements other than carbon in organic compounds. Published by Wiley-Hindawi, this journal provides researchers, professionals, and students with a platform to disseminate and access novel research findings related to the synthesis, properties, and applications of heteroatom-containing compounds. Since its inception in 1990 and gaining open access status in 2019, the journal has fostered academic collaboration and innovation throughout its converged years, although it currently holds a category quartile ranking of Q4 in Chemistry (miscellaneous) and ranks #319 out of 408 in general chemistry within Scopus. With its commitment to high-quality research and broad accessibility, Heteroatom Chemistry is poised to be an essential resource for anyone looking to explore the rich and varied applications of heteroatom chemistry in diverse scientific fields.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

ARCHIV DER PHARMAZIE is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to pioneering advances in the fields of Pharmaceutical Science and Drug Discovery. With an impactful history dating back to its inception in 1822, this journal is recognized for its significant contribution to the pharmaceutical sciences, maintaining an impressive Q2 ranking in both the Drug Discovery and Pharmaceutical Science categories as of 2023. The journal’s commitment to excellence is reflected in its Scopus rankings, placing it in the top tiers of relevant fields, ensuring a broad reach and impact among researchers and professionals. Although Open Access options are not available, ARCHIV DER PHARMAZIE continues to be an invaluable resource for scholars seeking to stay abreast of cutting-edge research and developments in pharmacy and related sciences. The journal’s contributions not only serve as crucial benchmarks in research but also enhance the understanding of pharmaceutical innovations, making it essential reading for both seasoned professionals and students alike.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading journal in the fields of biochemistry, drug discovery, and medicinal chemistry, designed to disseminate significant advances in these disciplines. Established in 1991, the journal spans various important categories, including Organic Chemistry and Pharmaceutical Science, with its 2023 Scimago Journal Rank placing it at Q2 in Organic Chemistry and Q3 in several other relevant fields. Though not an open-access publication, it provides invaluable insights into contemporary research and innovative methodologies, appealing to researchers, professionals, and students alike. The journal's commitment to quality and relevance makes it a vital resource for those aiming to stay at the forefront of bioorganic and medicinal chemistry developments. For more information, please visit the journal's website as it remains a critical platform for scholarly exchange, particularly for those engaged in interdisciplinary research.

JOURNAL OF MOLECULAR MODELING, published by Springer, is a pivotal resource for researchers and professionals in the fields of chemistry, computer science, and molecular sciences. The journal's ISSN is 1610-2940, with an E-ISSN of 0948-5023, reflecting its commitment to disseminating cutting-edge research from 1996 to 2024. Although the journal does not operate under an Open Access model, it remains an invaluable platform for the publication of innovative studies related to computational methods, theoretical chemistry, and molecular simulations. With a notable categorization across multiple quartiles—including Q4 in Catalysis and Q3 in Computational Theory and Mathematics—the journal holds a distinct rank in Scopus, highlighting its influence and contribution to the discipline. The importance of this journal lies in its ability to bridge the gap between theoretical understanding and practical applications, making it essential reading for students and scholars seeking to advance their knowledge and research in molecular modeling.

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.